Compare Cognizant Technology Solutions Corp (CTSH) vs Ginkgo Bioworks Holdings Inc (DNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cognizant Technology Solutions Corp vs Ginkgo Bioworks Holdings Inc — how do they compare? Cognizant Technology Solutions Corp trades at $57.21 (market cap $26.40B), while Ginkgo Bioworks Holdings Inc trades at $7.41 (market cap $505.73M). The key difference: Cognizant Technology Solutions Corp is far larger — about 52.2× Ginkgo Bioworks Holdings Inc's market cap, and Cognizant Technology Solutions Corp pays a 2.25% dividend while Ginkgo Bioworks Holdings Inc pays none. Which is the better fit depends on your goals.
| CTSH | DNA | |
|---|---|---|
Market Cap | $26.40B | $505.73M |
Sector | Technology | Health |
52-Week High | $86.70 | $16.14 |
52-Week Low | $38.73 | $5.48 |
Enterprise Value | $27.44B | $607.68M |
Dividend Yield | 2.25% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTSH trades at $58.31, up 1.11% today, near its consensus price target of $59.92. The stock shows bullish technical signals with moving averages supporting an uptrend, though oscillators indicate overbought conditions. Recent Q2 2026 earnings missed estimates, but revenue beat expectations, and the company maintains strong profitability with a net margin of 10.26%. AI initiatives and financial services growth are key drivers, as highlighted in recent earnings calls (Seeking Alpha, 2026-07-29).
Outlook: CTSH offers value with a P/E of 12.58 and stable cash flows, but faces risks from client spending caution and competitive pressures. Upside potential exists if AI investments yield growth, though macroeconomic headwinds could limit near-term gains. Analysts are mixed, with 43% recommending buy.
Ginkgo Bioworks (DNA) trades at $7.29, down 4.71% with bearish technical signals. The company reported Q2 2026 revenue of $20 million, down 48% year-over-year, continuing its strategic pivot to autonomous labs. Despite beating EPS expectations in two of the last three quarters, DNA shows negative profitability with -219.6% net income margin and negative cash flow. Analyst sentiment is mixed with 45% buy ratings but significant institutional selling pressure.
DNA faces substantial execution risk during its business transition, with declining revenue and persistent losses offset by potential in autonomous laboratory technology. The stock's current valuation at 3.61x sales appears stretched given negative earnings, requiring successful operational turnaround for sustainable recovery. Near-term catalysts depend on revenue stabilization and cost management improvements.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cognizant Technology Solutions Corp
Cognizant is a global IT services provider, offering consulting and outsourcing services to some of the world's largest enterprises spanning the financial services, media and communications, healthcare, natural resources, and consumer products industries. Cognizant employs nearly 300,000 people globally, roughly 70% of whom are in India, although the company's headquarters are in Teaneck, New Jersey.
Read more on CTSH →About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →
